Anti-IL-1β reference antibody (CDP484) is used in research to neutralize interleukin-1 beta (IL-1β), a key mediator of inflammation, in studies of inflammatory and autoimmune diseases such as rheumatoid arthritis and cryopyrin-associated periodic syndromes (CAPS). It serves as a reference standard in bioassays, immunoassays (e.g., ELISA), and drug development to evaluate the efficacy and specificity of anti-inflammatory biologics targeting IL-1β.